"10.1371_journal.pone.0129289","plos one","2015-06-08T00:00:00Z","Cl√©ment Fran√ßois; Nora Rahhali; Ylana Chalem; Per S√∏rensen; Amandine Luquiens; Henri-Jean Aubin","H. Lundbeck A/S, Issy les Moulineaux Cedex, France; H. Lundbeck A/S, 2500 Valby, Denmark; Assistance Publique-H√¥pitaux de Paris, H√¥pital Paul Brousse, INSERM U669, Villejuif Cedex, France","Conceived and designed the experiments: CF NR YC PS. Performed the experiments: CF NR YC PS AL HJA. Analyzed the data: NR YC PS. Contributed reagents/materials/analysis tools: CF NR HJA. Wrote the paper: CF NR HJA.","The authors have the following interests. The authors thank Steve Clissold and David Figgitt, Content Ed Net, for providing valuable editorial support in the preparation of the article. The study was funded by Lundbeck and funding for editorial support was provided by Lundbeck SAS, France. Lundbeck has European marketing approval for Selincro (nalmefene). Henri-Jean Aubin has received honoraria and travel grants from Lundbeck, Merck Serono, Ethypharm, D&A Pharma, Pfizer, and Bioprojet. Amandine Luquiens has received honoraria and travel grants from Lundbeck. Cl√©ment Fran√ßois, Nora Rahhali, Ylana Chalem, and Per S√∏rensen are employees of Lundbeck. There are no further patents, products in development or marketed products to declare. This does not alter their adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","06","Cl√©ment Fran√ßois","C√F√",6,TRUE,4,6,3,3,TRUE,FALSE,FALSE,0,NA,FALSE
